TrialThe Journal of infectious diseases2024

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.

Chijioke Bennett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.